Business Context and Reporting Period
Company: Metavia Inc. (MTVA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Metavia is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. Its primary pipeline consists of two assets: vanoglipel (DA-1241), a GPR119 agonist for metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 Diabetes, and DA-1726, a GLP-1/glucagon dual agonist for obesity. The company has no commercial revenue and relies on capital raises to fund operations.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(13.0) million | $(27.6) million |
| Operating Expenses | $13.7 million | $28.8 million |
| Research & Development (R&D) | $6.8 million | $21.6 million |
| General & Administrative (G&A) | $6.9 million | $7.3 million |
| Cash and Cash Equivalents (Year-End) | $10.3 million | $16.0 million |
| Accumulated Deficit | $(148.8) million | $(135.9) million |
| Net Cash Used in Operating Activities | $(15.7) million | $(24.7) million |
Note: The filing does not provide specific margin percentages as the company has no revenue. Debt levels are not explicitly detailed as a line item, though warrant liabilities of $0.1 million and related party payables of $3.3 million are recorded.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 52.4% (from $28.8 million to $13.7 million). This was driven primarily by a 68.4% reduction in R&D expenses ($14.8 million decrease), attributed to the close-out of the Phase 2a clinical trial for vanoglipel and reduced activities for DA-1726 in 2025 compared to 2024.
- Net Loss Improvement: Net loss narrowed significantly from $27.6 million in 2024 to $13.0 million in 2025.
- Capital Structure: The company completed a one-for-eleven reverse stock split in December 2025. As of December 31, 2025, there were 2,308,294 shares of common stock outstanding (post-split adjusted).
- Financing Activity: In 2025, the company raised approximately $10.0 million through a private placement and an "At The Market" (ATM) offering. In January 2026 (subsequent event), the company closed an underwritten public offering raising gross proceeds of $9.3 million.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Going Concern: The company has raised substantial doubt about its ability to continue as a going concern within one year of the report issuance due to recurring losses and an accumulated deficit. Management believes existing cash plus proceeds from the January 2026 offering will fund operations into the fourth quarter of 2026.
- Clinical Milestones:
- Vanoglipel (DA-1241): Positive topline results from the Phase 2a MASH trial were announced in December 2024. The Clinical Study Report (CSR) is expected to be finalized in the first half of 2026.
- DA-1726: Positive topline data from the Phase 1 MAD cohort (48 mg) was announced in January 2026, showing robust weight loss and glucose control. Phase 1 Part 3a and 3b titration studies are planned to start in April 2026, with data readouts expected in Q4 2026.
Risks and Contingencies
- Liquidity Risk: The company requires additional capital to continue operations. Failure to secure funding could force delays or termination of clinical trials.
- Related Party Dependence: Metavia relies on Dong-A ST Co., Ltd. (a related party owning ~39% of the company) for the exclusive license of its core assets and as the sole manufacturer for clinical supplies. A payable of $3.3 million is owed to Dong-A ST as of year-end.
- Regulatory Risk: No products are approved. Success depends on FDA approval, which is uncertain and costly.
- Stock Volatility: The company faces risks related to Nasdaq listing requirements, including a proposed minimum market value rule of $5 million.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $10.3 million year-end cash balance plus the $9.3 million January 2026 proceeds to fund operations through Q4 2026 as projected.
- Related Party Transactions: Review the terms of the $3.3 million payable to Dong-A ST and the manufacturing exclusivity agreement to assess supply chain risks.
- Clinical Data Finalization: Monitor the release of the finalized Clinical Study Report (CSR) for vanoglipel in H1 2026 to confirm the positive topline data.
- Capital Raise Terms: Examine the dilution impact of the January 2026 offering (Class A/B Units with warrants) and the remaining capacity under the ATM program.
- Going Concern Status: Assess the likelihood of future equity dilution or debt financing given the "substantial doubt" disclosure in the auditor's report.